Testosterone is a hormone that occurs naturally in the body, a prescription medication used to treat diagnosed hormone deficiency, and a federally controlled anabolic steroid, all at the same time. That combination is exactly why the question comes up so often from employees on prescribed testosterone replacement therapy (TRT) and from employers trying to understand what their drug testing program actually covers. The short answer is that a standard 5 to 12 panel workplace immunoassay screen, the kind built into most urine cups, dip cards and oral fluid devices, is not designed to detect testosterone at all. Finding testosterone or its metabolites requires a different, dedicated kind of laboratory test built specifically for anabolic agents. This article explains why the standard panel does not flag it, what anabolic agent testing actually measures, how a prescription changes the picture, and where the medical review officer (MRO) process fits in.
Why a standard workplace panel does not flag testosterone
Workplace drug testing panels are built around a defined, limited list of target analytes, not an open search for anything that might affect performance. Federal guidance on how these panels are structured and updated is published in the Mandatory Guidelines for Federal Workplace Drug Testing Programs, which centers the core federal panel on marijuana, cocaine, opiates, amphetamines and phencyclidine, with some non federal programs expanding to cover additional prescription controlled substance classes such as benzodiazepines or barbiturates. Testosterone and other anabolic steroids are not part of that core analyte list, and no commercial 5, 10 or 12 panel cup or dip card sold for general workplace use is built with an immunoassay antibody that reacts to testosterone. A negative result on a routine pre employment, random or post accident screen says nothing about testosterone use one way or the other. It simply means the panel was never designed to look for it.
This also means an employee using prescribed TRT, or a hormone therapy patient of any kind, will not trigger a flag on a routine workplace panel because of that prescription. The testosterone question only becomes relevant when a program has a specific reason to add a dedicated anabolic agent test on top of the standard panel.
Testosterone's legal status as a controlled substance
Testosterone is listed by name as a Schedule III controlled substance under the Controlled Substances Act's anabolic steroid category, codified at 21 CFR 1308.13, the Drug Enforcement Administration's regulation defining Schedule III substances. That listing is why testosterone products are prescription only and why DEA registration requirements apply to manufacturers, pharmacies and prescribers who handle them. Injectable and topical testosterone formulations used for diagnosed hypogonadism or other approved indications carry full prescribing information, including boxed warnings and controlled substance handling notices, in their official labeling, which is searchable on the National Library of Medicine's DailyMed label database. None of that changes what a standard workplace immunoassay panel is built to detect. Schedule III status governs how the drug is manufactured, prescribed and dispensed; it does not automatically mean a routine drug test screens for it, in the same way that many Schedule III and Schedule IV prescription medications are never included on a basic 5 panel cup.
How anabolic agent testing actually works
When a program does need to check for testosterone use, usually a sports governing body, a military command, or an employer with a specific safety or policy reason, laboratories use a different approach than a drug of abuse immunoassay. The traditional screening tool is the urinary testosterone to epitestosterone ratio, commonly called the T/E ratio, which compares the concentration of testosterone to its closely related, biologically inactive isomer. Because the body normally keeps those two compounds in a fairly stable relationship, an unusually elevated ratio can indicate that exogenous testosterone has been introduced. Published laboratory science describes the T/E ratio as the long standing first line screen for anabolic androgenic steroid misuse, with carbon isotope ratio mass spectrometry (IRMS) serving as the confirmation method that distinguishes the body's own testosterone from a synthetic, pharmaceutical source by measuring differences in carbon isotope composition; this two step screen and confirm structure is described in detail in a peer reviewed review of anti doping detection strategies published through the National Library of Medicine's PubMed Central archive. IRMS confirmation is more complex, slower and more expensive to run than a standard immunoassay, which is one reason it stays limited to verifying samples that already screened above a laboratory's established threshold rather than being run on every routine workplace sample.
It is worth being plain about what this means in practice for an employer. A standard dip card, cup or oral fluid device cannot be reconfigured on the fly to pick up testosterone. Programs that genuinely need anabolic agent detection contract separately for a T/E ratio screen with IRMS confirmation capability, which is a materially different service than ordering extra lanes on a standard panel.
Workplace panel versus anabolic agent panel
| Feature | Standard 5 to 12 panel workplace screen | Dedicated anabolic agent panel |
|---|---|---|
| Target substances | Marijuana, cocaine, opiates, amphetamines, PCP, and on expanded panels some additional prescription drug classes | Testosterone and related anabolic androgenic steroids |
| Screening method | Immunoassay (antibody reacts to a drug class) | Urinary testosterone to epitestosterone (T/E) ratio |
| Confirmation method | GC/MS or LC/MS/MS on any non negative screen | Carbon isotope ratio mass spectrometry (IRMS) |
| Who typically orders it | General employers, DOT covered transportation programs, pre employment and random testing | Sports governing bodies, military commands, and a limited number of employers with a specific policy reason |
| Review step | Medical review officer reviews any non negative confirmed result | Medical review officer or an equivalent documented review, with prescription history considered |
Prescribed TRT and what the MRO process looks at
An employee on legitimately prescribed TRT who is enrolled in a program that specifically screens for anabolic agents should expect the same review structure that applies to any other controlled substance result. A flagged screen goes to confirmation testing, and a non negative confirmed result is reviewed by a medical review officer, a licensed physician trained to evaluate laboratory data together with the donor's prescription and medical history before any result is reported as final. Programs that screen for anabolic agents at all are uncommon outside of sports and military settings, and background on how general workplace drug testing programs are structured, including the review expectations that responsible employers build into them, is available from the Substance Abuse and Mental Health Services Administration's workplace resources. This article does not provide dosing, treatment or diagnostic guidance of any kind; anyone with questions about a TRT prescription or a hormone therapy regimen should direct those questions to the prescribing physician, not to a drug testing vendor.
Employers designing or expanding a program that may need to address anabolic agents should also keep in mind that this kind of testing is not something a standard commercial cup or dip card can be adapted to perform, and policies covering it should be developed with qualified counsel given the specialized laboratory work, cost and review process involved.
Related reading
Readers comparing testosterone to other performance enhancing compounds that also fall outside standard panels may find it useful to read our articles on whether SARMs show up on a drug test and on how anabolic steroid testing works and who actually tests for it, both of which cover the same screen and confirm structure described above in more depth.
Frequently asked questions
Does testosterone show up on a standard workplace drug test?
No. Testosterone is not a target analyte on a standard 5 to 12 panel immunoassay screen. Detecting it requires a dedicated anabolic agent panel using the testosterone to epitestosterone ratio with carbon isotope ratio confirmation.
Is testosterone a controlled substance?
Yes. Testosterone is listed by name as a Schedule III controlled substance under the Drug Enforcement Administration's anabolic steroid schedule in 21 CFR 1308.13, which is why it is prescription only and subject to DEA handling rules.
Will prescribed TRT cause a positive result on a routine drug test?
A routine 5 to 12 panel screen is not built to detect testosterone, so prescribed TRT does not trigger that kind of test. In the rare case a program does run a dedicated anabolic agent test, a documented prescription history is the kind of information a medical review officer considers during result review.
What test actually detects testosterone use?
Laboratories use the urinary testosterone to epitestosterone (T/E) ratio as a screen, with carbon isotope ratio mass spectrometry (IRMS) used to confirm whether an elevated ratio came from a synthetic source rather than the body's own production.
Who actually orders anabolic agent testing?
This kind of testing is mainly used by sports governing bodies and military commands, along with a limited number of employers that have a specific safety or policy reason, rather than general civilian workplace drug programs.
Where can an employer source compliant workplace drug test supplies?
American Screening Corporation supplies drug test cups, dip cards and oral fluid tests built around standard workplace panels, available through the drug test cup collection and, for distributors, the wholesale portal.
This article is general information about drug testing science and procedure, not medical or legal advice. Employees and employers with questions about a specific prescription, test result or program design should consult a licensed physician, a medical review officer or qualified counsel.
